UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 10, 2008
WRIGHT MEDICAL GROUP, INC.
(Exact name of registrant as specified in charter)
| |
|
|
|
|
| Delaware
|
|
000-32883
|
|
13-4088127 |
| (State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer |
| of incorporation)
|
|
File Number)
|
|
Identification Number) |
| |
|
|
| 5677 Airline Road, Arlington, Tennessee
|
|
38002 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (901) 867-9971
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SEC Letter
On June 10, 2008, our principal operating subsidiary, Wright Medical Technology, Inc., received a
letter from the U.S. Securities and Exchange Commission informing us that it is conducting an
informal investigation regarding potential violations of the Foreign Corrupt Practices Act in the
sale of medical devices in a number of foreign countries by companies in the medical device
industry. We understand that several other medical device companies have received similar letters.
We intend to fully cooperate with this informal investigation.
1